CHRM2

Across TCGA pan-cancer cohorts, CHRM2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CHRM2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CHRM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHRM2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

ESCA, UCEC, and THYM are the cancer types where CHRM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	III,IV	0.074	0.574	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.941	0.426	.005	22	view →
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
PRAD	DFS	Median	All	0.617	0.886	.038	6	view →
STAD	OS	Median	III,IV	0.875	0.321	.033	5	view →
BLCA	DFS	Median	All	1.000	0.330	.036	4	view →
SCLC	OS	Median	IV	0.938	0.260	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CHRM2–ESCA (OS)

Open the ESCA breakdown →